EILEEN A. ELLIOTT is site lead for site affairs and external partnership at Pfizer Kendall Square. In this role she leads the strategy for external outreach, communications, colleague engagement, and site affairs related to Pfizer’s Cambridge R&D campus. In 1995, Elliott joined Pfizer as a research scientist in immunology and held positions of increasing responsibility. She has made pivotal contributions to drug discovery and the company’s business operations, including leading discovery and development of both small and large molecules for a range of therapeutic targets. A lead contributor to Xeljanz, Pfizer’s JAK3 modulator and Alexion’s Solaris product, Elliott has more than twenty five peer reviewed publications and numerous scientific presentations. She received her B.S. in biology from St. Bonaventure University, a Ph.D. in immunology from Albany Medical College, Union University, and completed a fellowship in Dr. Richard Favell’s laboratory at Yale University as a howard hughes fellow.